← Back to Clinical Trials
Recruiting NCT06867419

NCT06867419 Metabolic Features Effects on FAST Score in MASLD Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06867419
Status Recruiting
Phase
Sponsor Tanta University
Condition Metabolic Dysfunction-Associated Steatotic Liver Disease
Study Type OBSERVATIONAL
Enrollment 385 participants
Start Date 2024-09-01
Primary Completion 2025-03-30

Trial Parameters

Condition Metabolic Dysfunction-Associated Steatotic Liver Disease
Sponsor Tanta University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 385
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-09-01
Completion 2025-03-30
Interventions
Transient Elastography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this observational cross-sectional study is to evaluate the effect of metabolic features on Fibroscan-AST (FAST) score stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) patients in Egypt. Researchers will identify the metabolic risk factors in patients with MASLD. evaluate the effect of metabolic features on stratifying MASLD patients by predicting higher FAST score. Participants will be subjected to history taking, clinical examination, laboratory investigations, abdominal ultrasonography, and transient elastography (Fibroscan) to measure liver stiffness (LSM) and controlled attenuation parameter (CAP). The Non-alcoholic fatty liver disease (NAFLD) fibrosis score and FAST score will be calculated.

Eligibility Criteria

Inclusion Criteria: * All patients with MASLD who had steatosis detected by (VCTE-CAP) elastography Exclusion Criteria: * Patients with a history of significant alcohol consumption more than 30 g/day in men and \> 20 g/day in women. * Patients with positive hepatitis B or C virus markers. * Patients with autoimmune hepatitis. * Patients with any other metabolic liver disease. * Patients with hepatic focal lesions.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology